Ozempic 1mg Semaglutide Injection

Use Restrictions and Indications

Ozempic 1mg improve glycemic control in adults with type 2 diabetes mellitus and to lower the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, or nonfatal stroke) in adults with type 2 diabetes mellitus and established CV disease, Ozempic® (semaglutide) injection in dosages of 0.5 mg, 1 mg, or 2 mg is recommended.

Patients who have experienced pancreatitis in the past have not been studied with Ozempic®. In patients with a history of pancreatitis, take into account additional anti-diabetic treatments.

Diabetes mellitus type 1 individuals are not supposed to take Ozempic®.

Contraindications and Additional Important Safety Information

Patients who have MEN 2 or a personal or family history of MTC, as well as those who have experienced an allergic reaction to semaglutide or any of the excipients in Ozempic®, should not use the medication. With Ozempic®, severe hypersensitivity responses have been documented, including anaphylaxis and gioedema.

Precautions and Warnings
Risk of Thyroid C-Cell Tumors: If serum calcitonin is examined and found to be elevated or thyroid nodules are observed on physical examination or neck imaging, patients should be sent to an endocrinologist for further evaluation.

Pancreatitis: Clinical studies have documented both acute and chronic pancreatitis. Keep a close eye out for pancreatitis symptoms in patients (persistent severe abdominal pain, sometimes radiating to the back with or without vomiting). If pancreatitis is suspected, stop taking Ozempic® right away; if it is found to be true, do not take it again.

Diabetic Retinopathy Problems: In a 2-year study involving patients with type 2 diabetes and high cardiovascular risk, Ozempic®-treated patients experienced greater diabetic retinopathy complications (3.0%) than placebo-treated patients (1.8%). Patients having a history of diabetic retinopathy at baseline had a higher absolute risk increase for diabetic retinopathy complications than patients without a known history of the condition.
Temporary deterioration of diabetic retinopathy has been linked to rapid improvement in glucose control. There hasn’t been any research on how semaglutide’s long-term glycemic management affects diabetic retinopathy problems. Patients who have a history of diabetic retinopathy should be watched for its progression.

Never Share an Ozempic® Pen Between Patients: Even if the needle is changed, Ozempic® pens should never be shared between patients. Sharing pens increases the danger of spreading blood-borne infections.
Patients who take Ozempic® in conjunction with insulin or an insulin secretagogue (such as a sulfonylurea) run a higher risk of developing hypoglycemia, including severe hypoglycemia. The risk of hypoglycemia should be discussed with patients using these concurrent drugs, and they should be made aware of the symptoms and signs of hypoglycemia.

Acute Kidney Injury: Patients taking GLP-1 receptor agonists have been reported to experience acute kidney injury and worsening chronic renal failure, which occasionally requires hemodialysis. Some of these incidents have been documented in patients who don’t have kidney disease as an underlying condition. The majority of the recorded incidents were patients who had also suffered diarrhoea, dehydration, vomiting, or nausea. When starting Ozempic® or increasing doses in patients who are experiencing severe adverse gastrointestinal effects, keep an eye on renal function.

Hypersensitivity: Patients receiving Ozempic® have experienced serious hypersensitivity responses, such as anaphylaxis and gioedema. If hypersensitivity responses happen, stop taking Ozempic®, treat them right once in accordance with conventional medical procedure, and keep an eye on them until the symptoms go away. When administering another GLP-1 receptor agonist to a patient who has a history of angioedema or anaphylaxis, exercise caution.

Acute Gallbladder Disease: Postmarketing and clinical trials for GLP-1 receptor agonists have revealed reports of acute gallbladder disease symptoms such cholelithiasis and cholecystitis. Cholelithiasis was documented in placebo-controlled trials in 1.5% and 0.4% of individuals receiving Ozempic® 0.5 mg and 1 mg, respectively, but not in placebo-treated patients. Gallbladder tests and the proper clinical follow-up are recommended if cholelithiasis is suspected.

Negative Reactions
Nausea, vomiting, diarrhoea, abdominal discomfort, and constipation are the most frequent side effects associated with Ozempic® treatment, occurring in 5% or less of patients.
Adverse drug reactions
To lessen the risk of hypoglycemia when starting Ozempic®, think about lowering the dose of the concurrently prescribed insulin secretagogue (such sulfonylureas) or insulin.
Caution should be taken since Ozempic® delays stomach emptying and may affect how well oral drugs are absorbed when taken concurrently.

Use with Particular Populations
There is not enough information about semaglutide use during pregnancy to determine whether there is a drug-associated risk for poor developmental outcomes. Due to the lengthy washout period for semaglutide, stop taking Ozempic® in women at least two months before a planned pregnancy.